2018
Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications
LEGRAND, M., P.O. LUDES, Z. MASSY, P. ROSSIGNOL, Jiří PAŘENICA et. al.Základní údaje
Originální název
Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications
Autoři
LEGRAND, M. (250 Francie, garant), P.O. LUDES (250 Francie), Z. MASSY (250 Francie), P. ROSSIGNOL (250 Francie), Jiří PAŘENICA (203 Česká republika, domácí), J.J. PARK (410 Korejská republika), S. ISHIHARA (392 Japonsko), K.F. ALHABIB (682 Saúdská Arábie), A. MAGGIONI (380 Itálie), O. MIRO (724 Španělsko), N. SATO (392 Japonsko), A. COHEN-SOLAL (250 Francie), E. FAIRMAN (32 Argentina), J. LASSUS (246 Finsko), V.P. HARJOLA (246 Finsko), C. MUELLER (756 Švýcarsko), F. PEACOCK (840 Spojené státy), D.J. CHOI (410 Korejská republika), P. PLAISANCE (250 Francie), Jindřich ŠPINAR (203 Česká republika, domácí), M. KOSIBOROD (840 Spojené státy), A. MEBAZAA (250 Francie) a E. GAYAT (250 Francie)
Vydání
Clinical Research in Cardiology, Heidelberg, Springer, 2018, 1861-0684
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 4.907
Kód RIV
RIV/00216224:14110/18:00103657
Organizační jednotka
Lékařská fakulta
UT WoS
000425730100003
Klíčová slova anglicky
Mortality; Potassium; B-blockers; Heart failure; Renal failure
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 9. 2. 2019 20:41, Soňa Böhmová
Anotace
V originále
Background The interaction between chronic medications on admission and the association between serum potassium level and outcome in patients with acute heart failure (AHF) are unknown. Methods Observational intercontinental study of patients admitted with AHF. 15954 patients were included from 12 cohorts in 4 continents. Main outcome was 90-day mortality. Clinical presentation (medication use, hemodynamics, comorbidities), demographic, echocardiographic, and biochemical data on admission were recorded prospectively in each cohort, with prospective adjudication of outcomes. Results Positive and negative linear relationships between 90-day mortality and sK+ above 4.5 mmol/L (hyperkalemia) and below 3.5 mmol/L (hypo-kalemia) were observed. Hazard ratio for death was 1.46 [1.34-1.58] for hyperkalemia and 1.22 [1.06-1.40] for hypokalemia. In a fully adjusted model, only hyperkalemia remained associated with mortality (HR 1.03 [1.02-1.04] for each 0.1 mmol/l change of sK+ above 4.5 mmol/L). Interaction tests revealed that the association between hyperkalemia and outcome was significantly affected by chronic medications. The association between hyperkalemia and mortality was absent for patients treated with beta blockers and in those with preserved renal function. Conclusions In patients with AHF, sK+ > 4.5 mmol/L appears to be associated with 90-day mortality. B-blockers have potentially a protective effect in the setting of hyperkalemia.